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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYIn glioblastoma multiforme (GBM), brain-tumor-initiating cells (BTICs) with cancer stem cell characteristics have been identified and
proposed as primordial cells responsible for disease initiation, recurrence, and therapeutic resistance. However, the extent to which in-
dividual, patient-derived BTIC lines reflect the heterogeneity of GBM remains poorly understood. Here we applied a stem cell biology
approach and compared self-renewal, marker expression, label retention, and asymmetric cell division in 20 BTIC lines. Through cluster
analysis, we identified two subgroups of BTIC lines with distinct precursor states, stem- or progenitor-like, predictive of survival after
xenograft. Moreover, stem and progenitor transcriptomic signatureswere identified, which showed a strong associationwith the proneu-
ral and mesenchymal subtypes, respectively, in the TCGA cohort. This study proposes a different framework for the study and use of
BTIC lines and provides precursor biology insights into GBM.INTRODUCTION
Glioblastoma multiforme (GBM) is the most common
adult primary brain tumor, with an extremely dismal
prognosis and high rate of recurrence following standard
therapy (Wen and Kesari, 2008). Populations of brain tu-
mor initiating cells (BTICs), which express many of the
properties of cancer stem cells (CSCs), have been identi-
fied in GBM (Singh et al., 2004). BTICs display CSC
characteristics of long-term self-renewal, multilineage
differentiation, and tumorigenicity, which may be collec-
tively referred to as cancer ‘‘stemness’’ features (reviewed
in Clevers, 2011). BTIC lines have become a valuable
tool for modeling GBM (Westphal and Lamszus, 2011)
and for the development of experimental therapeutics
(Luchman et al., 2014).
In a recent review, Stopschinski and colleagues (Stop-
schinski et al., 2013) argued that a consensus standardiza-
tion of the BTIC model will be essential to harness its full
cell biologic and experimental therapeutic potential in a
heterogeneous disease such as GBM. Initial studies aimed
at examining single stemness characteristics, such as
dye retention (Deleyrolle et al., 2011) and self-renewal
(Campos et al., 2014), have provided insights as to the rela-
tionship between BTIC lines and tumor heterogeneity.
Nevertheless, a comprehensive precursor cell analysis of
multiple BTIC lines has yet to be performed.It has been suggested (Binda et al., 2014; Vescovi et al.,
2006) that understanding BTICs may best be achieved by
examining them in relation to normal neural stem cells
(NSCs). NSCs are organized in a hierarchical manner, with
a quiescent cell (Codega et al., 2014) at the apex. Through
asymmetric cell division (Shen et al., 2002; Sun et al.,
2005), the NSC self-renews, giving rise to an NSC and
transit-amplifying progenitor that proliferates rapidly and
produces the bulk of the short-term neurogenic population
(Doetsch et al., 1999a). Moreover, BTICs are most often
cultured with techniques originally developed for NSCs
(Reynolds andWeiss, 1992) and sharemany stemness char-
acteristics with NSCs, including the expression of markers
such as NESTIN, CD133, and SOX2 (Gangemi et al., 2009;
Singh et al., 2004), label retention (Deleyrolle et al., 2011),
asymmetric cell division (Lathia et al., 2011), and self-
renewal (Campos et al., 2014). However, a single study
employing multiple stemness characteristics to examine a
large set of heterogeneous BTIC lines has yet to be reported.
Hypothesizing that heterogeneity among BTIC lines is
related to differences in stemness features, we used a
comprehensive and integrated stem cell biology approach
to characterize 20 lines. We report the identification of
two groups, with distinct precursor states, predictive of
survival after xenografts and exhibiting strong gene ex-
pression profile associations with relevant subtypes of the
Cancer Genome Atlas (TCGA).Stem Cell Reports j Vol. 5 j 1–9 j July 14, 2015 j ª2015 The Authors 1
Figure 1. Complex Self-Renewal and
Marker Expression Patterns in BTICs
(A) Representative phase-contrast micro-
graph shows BTIC spheres in self-renewal
experiments.
(B) Quantification of sphere formation in
lines is shown.
(C–H) Expression of cell surface markers
common to BTICs and NSCs, EGFR (C and D),
CD133 (E and F), and CD15 (G and H), was
analyzed by FACS and quantified (D, F, and
H). (C), (E), and (G) show examples of the
FACS plots for BT147, BT134, and BT189.
Scale bar, 100 mm.
Error bars represent SEM (B, D, F, and H).
Each dot represents a single experiment. See
also Table S2.RESULTS
Heterogeneous Self-Renewal Ability and Marker
Expression within BTIC Lines
A comprehensive phenotypic characterization of 20 GBM
patient-derived BTIC lines, focusing on features of NSC
biology, was performed. The BTIC lines express, although
to variable degrees, NSC markers (NESTIN, SOX2,
MUSASHI1, VIMENTIN, CD15, and CD133) (Figure S1);
differentiate to express neuronal, astrocytic, and oligoden-
drocytic markers (Figure S1); and are tumorigenic, suggest-
ing that they contain true CSCs. Furthermore, they exhibit
mutations/deletions typically found in GBM (EGFR, TP53,
PTEN, NF1, and CDKN2A) (Table S1).
BTIC self-renewal capacity was assessed by calculating
the percentage of cells capable of giving rise to a new sphere2 Stem Cell Reports j Vol. 5 j 1–9 j July 14, 2015 j ª2015 The Authorsafter dissociation. A high degree of variability was observed
across the lines, with sphere-forming cells ranging from
7.8% ± 0.2% (mean ± SEM) to 22.3% ± 0.3% (Figures 1A
and 1B; inter-line differences were significant, p < 0.0001,
one-way ANOVA). Expression of NSC and BTIC markers
EGFR, CD133, and CD15 was analyzed by fluorescence-
activated cell sorting (FACS) (Figures 1C–1H), and a remark-
able inter-line diversity was again observed, with the
percentage of positive cells ranging from 2.6% ± 0.2% to
93.3% ± 1.1% for EGFR, from 0.4% ± 0.2% to 81.5% ±
2.3% for CD133, and from 0.2% ± 0.1% to 93.7% ± 1.9%
for CD15 (for all, p < 0.0001, one-way ANOVA).
Quiescence and Asymmetry in BTICs
Quiescence, the reversible exit from the cell cycle, is a pro-
cess common to NSCs and BTICs. Due to slower cellular
turnover, quiescent cells can be detected by the retention of
a dye or label (Cheung and Rando, 2013). The abundance
of label-retaining cells was assayed with carboxyfluorescein
diacetate succinimidylester (CFSE). While a large number
of cells were CFSE negative, a substantial population re-
mained clearly labeled after growth in standard conditions
(Figures 2A and 2C). Cells that divided only once or twice,
as determined by the intensity of fluorescence, were
defined as CFSEHIGH. These cells were functionally quies-
cent, as confirmed by the ability of both CFSEHIGH- and
CFSELOW-sorted cells to form new spheres (Figure S2).
Analysis of the percentage of label-retaining cells in all
BTIC lines showed different frequencies (Figure 2E),
ranging from 0.4% ± 0.1% to 5.2% ± 1.1% (p < 0.0001,
one-way ANOVA). The presence of label-retaining cells
in each line showed a weak inverse correlation to sphere
formation and a positive correlation with the percentage
of CD133+ cells, but not with the other stemness parame-
ters (Table S2).
Asymmetric cell division is a key step in the homeostatic
self-renewal of stem cells and has been previously described
in BTICs (Lathia et al., 2011). Using key markers of NSC
biology, we analyzed the frequency of asymmetry in
BTIC lines by assaying patterned asymmetric distribution
of NUMB, EGFR, NESTIN, and GFAP, after cell division.
Single cells were plated at low density, synchronized,
and analyzed 18–20 hr after the cell division block was
removed. Clear examples of asymmetric cell division (Fig-
ure 2F) could be found for all four markers. Similar results
were observed using additional NSC/BTIC markers
(CD133, SOX2, MUSASHI1, and CD15; data not shown).
Quantification showed that asymmetric cell division, while
very common in some BTIC lines (up to 46.4% ± 5.4% of
couples), was virtually non-existent in others (Figure 2G).
The inter-line differences were significant for all markers
(p < 0.0001, one-way ANOVA). Interestingly, the asym-
metric division rate did not correlate with the expression
of each individual marker, except for GFAP (Figure S3).
Cluster Analysis Reveals Two Distinct Precursor
State Groups
To understand parameters relevant to the biology of BTIC
lines, we first attempted to find direct correlations between
all pairs of assays performed (Table S2). Although some as-
sociations were found, no unifying pattern was identified.
Instead, using hierarchical clustering with Manhattan dis-
tance and Ward’s agglomeration method, we identified
two clusters (Figure 3A). K-means clustering with Manhat-
tan distance confirmed a two-cluster solution, and the
same membership in these two clusters was found (data
not shown). We next looked at which variables defined
the clustering of BTIC lines in each of these groups. Cluster
A was characterized (Z scores > 1.96) by stem cell features,such as higher levels of asymmetry, label-retaining cells,
and CD133-expressing cells, suggesting that these BTICs
may be more akin to classically defined stem cells (stem-
like: SL). Cluster B was defined by higher sphere formation
rate, resembling transit-amplifying progenitors found
in normal neurogenesis (progenitor-like: PL). Given the
resemblance of SL and PL cells to the NSC biology counter-
parts, we defined these features of the two BTIC groups as a
difference in precursor state. Interestingly, neither of the
two clusters associated with specific molecular alterations
in any of the genes analyzed (Fisher’s exact test, p > 0.05
for each mutation).
Precursor States Associate with Survival in Xenografts
We next examined whether SL or PL features of BTICs play
a defining role in tumor formation, by implanting 15 lines
in immunocompromised mice. All BTIC lines were tumor-
igenic (Figures 3B and 3C), but, notably, animals xeno-
grafted with SL lines survived significantly longer than
those implanted with PL lines (average median survival
SL = 183.7 ± 24.5 versus PL = 67.4 ± 11.4 days, p <
0.0001, log-rank test; SL n = 42, PL n = 59) (Figure 3D;
detailed survival times in Table S3).
To test whether the survival difference was due to varia-
tions in BTIC proliferation rates, we measured the growth
kinetics of 16 lines in vitro (eight for each group). Although
cells in SL lines divided slower (doubling time 4.58 ± 0.36
in SL versus 3.57 ± 0.19 days in PL, p < 0.0001), survival
in vivo was not correlated with the mean doubling time
observed in culture (Figure 3E; p = 0.41, R = 0.25), indi-
cating that shorter survival was not solely due to a differ-
ence in proliferation rate. In contrast, median survival
showed an inverse correlation with the abundance of
sphere-forming cells (Figure 3F; p = 0.03, R = 0.56).
Transcriptome Analysis Identifies an Association
between Precursor States and GBM Subtypes
RNA sequencing (RNA-seq) was performed on seven BTIC
lines from each group. Unsupervised clustering based on
the GBM subtype transcriptomic signatures (Verhaak
et al., 2010) did not distinguish proneural, mesenchymal,
classical, or neural BTICs. We then performed differential
expression analysis and found that 1,110 genes were sig-
nificantly upregulated in SL-BTICs and 269 genes were
upregulated in PL-BTICs (Figure 4A). We then derived
a signal-to-noise measure (DSN) to eliminate genes with
high SD within either BTIC group, and ultimately we
selected the top tenth percentile of differentially expressed
genes based on DSN, generating a signature of 136 genes
(Figure S4).
To further understand the relevance of this signature in
the disease context, we used the publicly available GBM
transcriptome dataset (Cancer Genome Atlas ResearchStem Cell Reports j Vol. 5 j 1–9 j July 14, 2015 j ª2015 The Authors 3
Figure 2. Heterogeneous Representation of Quiescent and Asymmetrically Dividing Cells in BTIC Lines
(A–E) CFSE-retaining cells (green in A and C) and by FACS (B and D; day 0, freshly labeled cells). Percentage of label-retaining cells is shown
in (E); individual dots represent independent experiments; error bars represent SEM. DIC, differential interference contrast.
(F) Examples of asymmetric distribution of the markers EGFR, NUMB, NESTIN, and GFAP are shown.
(G) Quantification of asymmetric cell division across the 20 BTIC lines. Each bar is the average of at least four independent experiments.
Errors bars represent SEM.
Scale bars, 50 mm (A and C) and 10 mm (F). See also Figure S2 and Table S2.
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Figure 3. Cluster Analysis Defines Precursor States of BTICs, Associated with Survival In Vivo
(A) Heatmap representing unsupervised clustering of 20 BTIC lines based on the parameters studied above. The lines within the two
clusters were found to be SL or PL.
(B and C) Representative images of tumor formation after xenograft. BTICs were visualized by human-specific nucleolin staining.
(D) Kaplan-Meier survival curves represent the individual BTICs (light lines) and the combined for each group (bold lines) (n = 5–10 mice
per cell line; total SL, n = 42; total PL, n = 59; p < 0.0001 in log-rank test statistic; see also Table S3 for specific survival and number of
animals per line).
(E) The growth rate of 12 BTIC lines in vitro was not correlated to median survival (Pearson’s correlation, p = 0.44, R = 0.23; for each line,
n = 3 independent experiments).
(F) The frequency of sphere-forming cells showed an inverse correlation to the median survival in 15 BTIC lines (Pearson’s correlation,
p = 0.03, R = 0.56; sphere formation data from experiments reported in Figure 1).
Scale bars, 1 mm (B and C) and 50 mm (insets).Network, 2008). To match the precursor state profiles with
samples in the TCGA dataset, we calculated Z scores for
genes overexpressed in SL- and PL-BTIC lines (referred to
as SL- and PL-genes, respectively) for each GBM patient
in the dataset. A combined average Z score, hereafter
referred to as Z0, was calculated by subtracting the average
PL-gene Z score from the average SL-gene Z score, for
each TCGA patient. Z0 was used as a summary measure of
similarity to either the SL or the PL group. Notably, in the
152 TCGA samples that were already classified into the
four GBM subtypes described previously (Verhaak et al.,
2010), there was a significant difference in Z0 between pro-
neural and mesenchymal tumors (p < 0.0001, one-way
ANOVA with Bonferroni post hoc analysis) (Figure 4B).The patient samples were then separated into three
groups, based on Z0 values (Z0 cutoff 0.1 and 0.1; groups I,
II, and III, n = 44, 40, and 68, respectively; Figure 4C). There-
fore, for the 136-gene profile, group I (Z0 > 0.1) had a pattern
of expression similar to SL lines and group III (Z0 < 0.1)
similar to PL lines. Group I was predominantly composed
of proneural samples (45.5%) and group III had mostly
mesenchymal (51.5%) (c2 =30.20,df=6,p<0.0001);no spe-
cific subtype was over-represented in group II (Figure 4D).
To further confirm the associations between groups
defined by our 136-gene signature and GBM subtypes, we
performed gene set enrichment analysis (GSEA) of genes
that define the four GBM subtypes (Verhaak et al., 2010)
within the TCGA dataset (Figure 4E). As expected, weStem Cell Reports j Vol. 5 j 1–9 j July 14, 2015 j ª2015 The Authors 5
Figure 4. Transcriptome Analysis Reveals
an Association between Precursor States
and Proneural and Mesenchymal Subtypes
(A) Initial selection of genes differentially
expressed in our two groups of seven lines
each is shown. RPKM, reads per kilobase per
million.
(B) Combined average Z scores (Z0) of TCGA
patient samples divided by GBM subtype are
shown. *p < 0.05, ****p < 0.0001.
(C) TCGA samples were ranked based on
Z0 and divided into three groups (Z0 > 0.1,
0.1 < Z0 < 0.1, and Z0 < 0.1).
(D) Pie charts represent the distribution of
GBM subtypes within the three groups.
(E) Representative gene set enrichment
analysis comparing groups I and III for the
enrichment of GBM subtype gene sets. All
genes are ranked based on the expression in
the dataset (bottom; subtype-specific genes
are correlated to the ranking, resulting in
the enrichment score. See also Table S4 for
complete analysis of the three groups.
(F) Clustergram shows the expression of the
136-gene signature in proneural and
mesenchymal samples.
TCGA data (B–F) were from 152 samples.
See also Figure S4.observed a strong enrichment of proneural-signature genes
in group I (p < 0.05, false discovery rate [FDR] < 0.10).
Conversely, the mesenchymal gene set was enriched in
group III (p < 0.05, FDR < 0.05). A complete list of associa-
tions is reported in Table S4. Patient survival was not signif-
icantly different across the three groups (p = 0.25, log-rank;
data not shown).
Finally, we asked whether our 136-gene precursor state
signature could effectively stratify the proneural (n = 38)
and mesenchymal (n = 49) patients in the TCGA dataset.
In unsupervised clustering (Figure 4F), our signature segre-
gated proneural and mesenchymal GBM samples, further6 Stem Cell Reports j Vol. 5 j 1–9 j July 14, 2015 j ª2015 The Authorsconfirming the relationship between these subtypes and
BTIC precursor states. SL genes significantly overlapped
with the cluster of genes overexpressed in proneural
patients (hypergeometric p = 0.001). Similarly, PL genes
overlapped significantly with those overexpressed in
mesenchymal patients (hypergeometric p = 0.001).DISCUSSION
By applying cluster analysis to the study of stemness prop-
erties of BTICs, we report the emergence of two distinct
groups of patient-derived BTIC lines. Utilizing concepts
taken from NSC biology, we defined these two groups as
SL and PL. Mice xenografted with PL lines showed strik-
ingly shorter median survival, which was not simply due
to their higher proliferation rate. Given that SL- and PL-
BTICs both contain CSCs, yet show remarkable differences
in vitro and in vivo,we propose that they differ in precursor
state. Our model provides a conceptual link between BTICs
and NSCs, which may be critical in developing a better
understanding of GBM. This is highlighted by the fact
that the gene expression signatures derived from SL and
PL lines were found to associate with GBM subtypes,
further underscoring the differences between the two
groups of BTIC lines.
The CSC hypothesis hinges on the presence of a hierar-
chical organization within a tumor (Kreso and Dick,
2014), reminiscent of normal stem cell biology, which re-
sults in a heterogeneous cell population. Furthermore,
diverse genetic and mutational backgrounds, as well as dif-
ferences in disease evolution, can result in heterogeneity
among CSCs (Meacham and Morrison, 2013). BTICs are
a widely used model for GBM but show great inter-line
heterogeneity (Stopschinski et al., 2013), mirroring the
inherent heterogeneity of GBM, recently observed even
at the single-cell level within and between patient tumors
(Patel et al., 2014).
Others previously have used in vitro growth characteris-
tics in attempts to identify subgroups among BTIC lines.
Gu¨nther and colleagues (Gu¨nther et al., 2008) classified
BTICs based on free-floating or adherent growth, finding
that they had different gene expression and in vivo
behavior. Clonogenicity, measured in a colony formation
assay, was the basis of the classification proposed by
Campos et al. (2014). Interestingly, this group found that
highly clonogenic lines had fewer label-retaining cells
and were more aggressive, a pattern resembling our find-
ings. Recently, Mao and colleagues (Mao et al., 2013) iden-
tified and characterized two mutually exclusive glioma
stem cell subtypes. Transcriptomic analysis distinguished
proneural and mesenchymal groups, and the latter
displayed more aggressive phenotypes both in vitro and
in vivo as well as increased resistance to radiation
compared with the proneural group. These studies offer
interesting insights in BTIC biology and help strengthen
our conclusions. Importantly, by taking a multi-dimen-
sional stem cell biology approach, our study also allowed
the identification of two BTIC subgroups that appear high-
ly relevant to the subtypes in the TCGA dataset.
Expression profiles from tumor tissue and derived cell
lines are extremely different, thus the current transcrip-
tomic signature for GBM subtyping may not apply
in vitro. Using our precursor state signature, we were
able to identify an association with the proneural andmesenchymal subtypes. Interestingly, it has been proposed
that, upon recurrence, GBMs tend to shift toward the
mesenchymal subtype (Phillips et al., 2006), suggesting
that the latter might be downstream in hierarchy. At the
same time, proneural GBMs show a worse response to stan-
dard therapeutic treatment (Verhaak et al., 2010), as would
be expected for stem-like cells. Moreover, Ozawa et al.
(2014) recently showed that most GBMs might derive
from a common proneural-like precursor. These reports
suggest that the mesenchymal subtype may be down-
stream of the proneural. Our study provides a possible
interpretation of these data, in the context of stem cell
biology. SL-BTICs would be less dysregulated, maintaining
more normal stem cell features; this would be reflected in
longer survival of xenografted mice and in the fact that
they are associatedwith the proneural subtype. In addition,
the SL lines may be more CSC-like and, hence, possibly
have a larger fraction of tumor-initiating cells; while dis-
playing less aggressive growth, they may be more tumori-
genic in vivo. This premise needs be confirmed by xeno-
grafting smaller numbers of cells in tumorigenicity
studies. Furthermore, our data suggest that the precursor
state model will be essential to test hypotheses in cancer
cell lineage and tumor evolution, currently assessed with
mouse models (Ozawa et al., 2014).
The precursor state model offers the conceptual basis for
developing more targeted GBM cell biology and experi-
mental therapeutic studies. SL lines may be more useful
to study tumor recurrence and hierarchy, while PL-BTICs
might be best employed to investigate the pathways
involved in rapid and aggressive growth. It is conceivable
that the precursor state also could influence response to
cytotoxic treatment in BTICs, as it does in NSCs. For
example, neural progenitors in adult mouse brain are abla-
ted easily by treatment with the chemotherapy agent cytar-
abine, while the quiescent stem cells are able to survive and
repopulate the subventricular zone (Doetsch et al., 1999b).
Failure of several targeted therapies, both in experi-
mental and clinical settings (Ohka et al., 2012), is a grim
reminder of the complexity and heterogeneity of GBM.
Here we provide a fresh classification of BTICs using a
classic stem cell biology approach combined with cluster
analysis. Improved characterization of BTICs, as a model
of GBM, will allow for a better understanding of their
response to treatment, both in vitro and in vivo, and ulti-
mately open the way for findings of high relevance to
GBM therapeutics.EXPERIMENTAL PROCEDURES
BTIC Cultures and Growth Assays
BTIC lines (n = 20) were isolated, established, and maintained as
described previously (Kelly et al., 2009). Lines were used withinStem Cell Reports j Vol. 5 j 1–9 j July 14, 2015 j ª2015 The Authors 7
25–30 passages of establishment fromprimary cells. For sphere for-
mation assays, 1,000 cells per well were plated (n = 6) and spheres
were counted when they reached a diameter of 200–250 mm. For
growth curves, cells were seeded at specific densities and ala-
marBlue (Life Technologies) conversion was measured every day
over the course of 2 weeks.
Flow Cytometry
Single-cell suspensionswere labeledwith appropriately conjugated
antibodies and analyzed with an ATTUNE flowcytometer (Life
Technologies). For label retention studies, single cells were stained
with 1 mM CFSE (Life Technologies) and grown in standard
conditions.
Asymmetry Studies
Asymmetry was analyzed by plating cells at low density, synchro-
nizing them with nocodazole or thymidine (Sigma); the block was
released and the cells were fixed and stained after 18–20 hr. Asym-
metric distribution ofmarkers was counted in at least 80 couples of
daughter cells.
In Vivo Studies
Cells (100,000) were implanted in the right striatum of 6- to 8-
week-old female C17/SCID mice (n = 6–10 per line). Animals
were euthanized upon demonstration of overt disease symptoms.
RNA-Seq and Analyses
RNA-seq was performed using HiSeq2000 (Illumina). The list of
differentially expressed genes was derived using DEfine v.0.9.2
(FDR cutoff of 0.01). Ranking of the TCGA samples was performed
by subtracting the average Z scores of SL genes by the average Z
scores of PL genes (Z0), then dividing the dataset in three groups
based on Z0 (TCGA data Ver.2014-08-28).
Statistical Analyses
All data reported for in vitro experiments are representative of at
least three independent replicates and are illustrated in scatterplots
or bar graphs, including mean ± SEM. Statistical analyses and
graphing were performed with Prism 6.0 (GraphPad), SPSS (IBM),
and R (version 3.0.1).
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